Literature DB >> 22920495

Comparative transcriptomic analyses of atopic dermatitis and psoriasis reveal shared neutrophilic inflammation.

David F Choy1, Daniel K Hsu, Dhaya Seshasayee, Maxwell A Fung, Zora Modrusan, Flavius Martin, Fu-Tong Liu, Joseph R Arron.   

Abstract

BACKGROUND: Atopic dermatitis (AD) and psoriasis are common inflammatory diseases canonically described as involving distinct T(H) polarization and granulocytic infiltration. Acute AD lesions are associated with T(H)2 and eosinophilic inflammation, whereas psoriatic lesions are associated with T(H)1/T(H)17 and neutrophilic inflammation. Despite intensive investigation, these pathways remain incompletely understood in vivo in human subjects.
OBJECTIVE: Using AD and psoriatic lesional skin as exemplar T(H)2 and T(H)1/T(H)17 diseased tissue, we sought to clarify common and unique molecular and pathophysiologic features in inflamed skin with different types of inflammatory polarization.
METHODS: We conducted gene expression microarray analyses to identify distinct and commonly dysregulated expression in AD (based on Hanifin and Rajka criteria) and psoriatic lesions. We defined gene sets (GSs) as comprising genes encoding cytokines, chemokines, and growth factors that were uniquely or jointly dysregulated in patients with AD and those with psoriasis and calculated aggregate GS expression scores for lesional skin of patients with these dermatoses and healthy control skin.
RESULTS: The atopic dermatitis gene set (AD-GS) score correlated with systemic and local measures of allergic inflammation, including serum IgE levels, blood eosinophil counts, and tissue eosinophil counts. Unexpectedly, genes encoding neutrophil chemoattractants among the common GS were highly expressed in AD lesional skin. Hematoxylin and eosin and immunohistochemical analyses showed the numbers of neutrophils in AD lesional skin were comparable with those in psoriatic lesional skin, and both were correlated with the extent of expression of neutrophil chemoattractant genes.
CONCLUSION: These data are evidence that neutrophilic inflammation is a feature of lesional AD pathology comorbid with allergic inflammation.
Copyright © 2012 American Academy of Allergy, Asthma & Immunology. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22920495      PMCID: PMC3511596          DOI: 10.1016/j.jaci.2012.06.044

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  52 in total

Review 1.  Normal cutaneous wound healing: clinical correlation with cellular and molecular events.

Authors:  Christian L Baum; Christopher J Arpey
Journal:  Dermatol Surg       Date:  2005-06       Impact factor: 3.398

2.  Differential expression of GRO-alpha and IL-8 mRNA in psoriasis: a model for neutrophil migration and accumulation in vivo.

Authors:  R Gillitzer; U Ritter; U Spandau; M Goebeler; E B Bröcker
Journal:  J Invest Dermatol       Date:  1996-11       Impact factor: 8.551

3.  Maintenance and polarization of human TH2 central memory T cells by thymic stromal lymphopoietin-activated dendritic cells.

Authors:  Yui-Hsi Wang; Tomoki Ito; Yi-Hong Wang; Bernhard Homey; Norihiko Watanabe; Rachel Martin; Christopher J Barnes; Bradley W McIntyre; Michel Gilliet; Rakesh Kumar; Zhengbin Yao; Yong-Jun Liu
Journal:  Immunity       Date:  2006-06       Impact factor: 31.745

4.  Epicutaneous sensitization with protein antigen induces localized allergic dermatitis and hyperresponsiveness to methacholine after single exposure to aerosolized antigen in mice.

Authors:  J M Spergel; E Mizoguchi; J P Brewer; T R Martin; A K Bhan; R S Geha
Journal:  J Clin Invest       Date:  1998-04-15       Impact factor: 14.808

5.  Integrative responses to IL-17 and TNF-α in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis.

Authors:  Andrea Chiricozzi; Emma Guttman-Yassky; Mayte Suárez-Fariñas; Kristine E Nograles; Suyan Tian; Irma Cardinale; Sergio Chimenti; James G Krueger
Journal:  J Invest Dermatol       Date:  2010-11-18       Impact factor: 8.551

6.  Use of monoclonal antibody against human neutrophil elastase in normal and leukaemic myeloid cells.

Authors:  K A Pulford; W N Erber; J A Crick; I Olsson; K J Micklem; K C Gatter; D Y Mason
Journal:  J Clin Pathol       Date:  1988-08       Impact factor: 3.411

7.  How does multiple testing correction work?

Authors:  William S Noble
Journal:  Nat Biotechnol       Date:  2009-12       Impact factor: 54.908

Review 8.  Thymic stromal lymphopoietin and OX40 ligand pathway in the initiation of dendritic cell-mediated allergic inflammation.

Authors:  Yong-Jun Liu
Journal:  J Allergy Clin Immunol       Date:  2007-08       Impact factor: 10.793

9.  Concerted expression of eotaxin-1, eotaxin-2, and eotaxin-3 in human bronchial epithelial cells.

Authors:  Akiko Komiya; Hiroyuki Nagase; Hirokazu Yamada; Takashi Sekiya; Masao Yamaguchi; Yasuyuki Sano; Nobuo Hanai; Akiko Furuya; Ken Ohta; Kouji Matsushima; Osamu Yoshie; Kazuhiko Yamamoto; Koichi Hirai
Journal:  Cell Immunol       Date:  2003-10       Impact factor: 4.868

10.  Semi-supervised methods to predict patient survival from gene expression data.

Authors:  Eric Bair; Robert Tibshirani
Journal:  PLoS Biol       Date:  2004-04-13       Impact factor: 8.029

View more
  31 in total

Review 1.  New and Potential Treatments for Atopic Dermatitis: Biologicals and Small Molecules.

Authors:  Mario Sánchez-Borges; Arnaldo Capriles-Hulett; Jose Antonio Ortega-Martell; Ignacio Ansotegui Zubeldia
Journal:  Curr Allergy Asthma Rep       Date:  2019-02-28       Impact factor: 4.806

2.  [Psoriasis vulgaris in children and adolescents. Pathogenesis, clinical picture and therapy].

Authors:  P H Höger; H Hamm
Journal:  Hautarzt       Date:  2015-04       Impact factor: 0.751

3.  Attenuated neutrophil axis in atopic dermatitis compared to psoriasis reflects TH17 pathway differences between these diseases.

Authors:  Nikhil Dhingra; Mayte Suárez-Fariñas; Judilyn Fuentes-Duculan; Julia K Gittler; Avner Shemer; Assaf Raz; Vincent A Fischetti; James G Krueger; Emma Guttman-Yassky
Journal:  J Allergy Clin Immunol       Date:  2013-06-15       Impact factor: 10.793

Review 4.  Cross-Disease Transcriptomics: Unique IL-17A Signaling in Psoriasis Lesions and an Autoimmune PBMC Signature.

Authors:  William R Swindell; Mrinal K Sarkar; Yun Liang; Xianying Xing; Johann E Gudjonsson
Journal:  J Invest Dermatol       Date:  2016-05-17       Impact factor: 8.551

5.  Galectin-7 downregulation in lesional keratinocytes contributes to enhanced IL-17A signaling and skin pathology in psoriasis.

Authors:  Hung-Lin Chen; Chia-Hui Lo; Chi-Chun Huang; Meng-Ping Lu; Po-Yuan Hu; Chang-Shan Chen; Di-Yen Chueh; Peilin Chen; Teng-Nan Lin; Yuan-Hsin Lo; Yu-Ping Hsiao; Daniel K Hsu; Fu-Tong Liu
Journal:  J Clin Invest       Date:  2021-01-04       Impact factor: 14.808

6.  Staphylococcus aureus Lipoteichoic Acid Damages the Skin Barrier through an IL-1-Mediated Pathway.

Authors:  Anne M Brauweiler; Elena Goleva; Donald Y M Leung
Journal:  J Invest Dermatol       Date:  2019-02-16       Impact factor: 8.551

7.  Skin tape sampling technique identifies proinflammatory cytokines in atopic dermatitis skin.

Authors:  Taras Lyubchenko; Hannah K Collins; Elena Goleva; Donald Y M Leung
Journal:  Ann Allergy Asthma Immunol       Date:  2020-09-05       Impact factor: 6.347

Review 8.  New insights into atopic dermatitis: role of skin barrier and immune dysregulation.

Authors:  Donald Y M Leung
Journal:  Allergol Int       Date:  2013-06       Impact factor: 5.836

Review 9.  Deciphering the complexities of atopic dermatitis: shifting paradigms in treatment approaches.

Authors:  Donald Y M Leung; Emma Guttman-Yassky
Journal:  J Allergy Clin Immunol       Date:  2014-10       Impact factor: 10.793

10.  Killer cell immunoglobulin-like receptor gene associations with autoimmune and allergic diseases, recurrent spontaneous abortion, and neoplasms.

Authors:  Piotr Kuśnierczyk
Journal:  Front Immunol       Date:  2013-01-29       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.